2015 FAST Science Summit

• 2015 Educational Summit: Panel Discussion
  Join experts Linda Burkhart, Gayle Porter, David Koppenhaver, and Susan Norwell as they discuss education and communication for children with special needs at the 2015 FAST Science Summit.
• 2015 Science Summit: Disruptive Nutrition
  Explore the 2015 Science Summit’s talk on Disruptive Nutrition’s innovative ketone supplement for Angelman Syndrome. Learn about ketones, their benefits, and the product development process.
• AS drug screening, mechanisms regulating imprinting of UBE3A and new animal models of AS
  Explore the FIRE project’s research on Angelman syndrome (AS), focusing on understanding UBE3A imprinting, identifying new treatments through high-throughput screening, and developing new animal models for AS.
• Behavioral differences seen in AS, new potential outcome measures in AS and synaptic function in the AS model
  Explore the FIRE initiative’s collaborative research on Angelman Syndrome (AS), new outcome measures in AS clinical trials, synaptic function in AS models, and the enzymatic activity of UBE3A. Dive into the future of AS treatment.
• Developing accessible, autonomous communication for AAC-using children: long-term outcomes and evidence-informed practices
  Explore the development of accessible, autonomous communication for AAC-using children. Understand the concepts, long-term outcomes, and evidence-informed practices to ensure effective communication.
• Emergent and conventional literacy: core principles, strategies, and decision-making
  Explore the principles of emergent and conventional literacy with Susan Norwell and David Koppenhaver. Discover tailored strategies for children with disabilities, including shared reading and personalized writing experiences.
• FAST FIRE Team Q&A
  Join the FAST FIRE team as they discuss Angelman research, gene therapy safety, and the challenges of drug delivery in the brain. Insights from a Q&A session at the 2015 FAST Science Summit.
• Introduction and Therapeutics in Angelman Syndrome
  Join us at the 2015 FAST Science Summit for the latest on Angelman Syndrome research and therapies. Learn about its genetics, current treatments, and promising future therapeutics.
• Progress in designing epigenetic regulators for persistent UBE3A activation
  Explore the progress in designing epigenetic regulators for persistent UBE3A activation, a potential treatment for Angelman Syndrome. Discover the research, challenges, and promising results from UC Davis.
• Protein replacement therapy using gene delivery
  Explore Dr. Kevin Nash’s innovative research on protein replacement therapy using gene delivery. Learn about the advantages of AAV, its potential in treating neurological diseases, and methods for broader distribution in the brain.
• Seizures and behavioral phenotypes in the AS mice and use of this information in preclinical trials
  Explore Dr. Anne Anderson’s research on seizures and behavioral phenotypes in Angelman syndrome mice, and its application in preclinical trials for potential treatments.
• The use of Gaboxadol (OV101) in the treatment of Angelman Syndrome. Down stream therapeutics working at the neuronal synapse. Discussion of future clinical trials
  Explore the potential of Gaboxadol (OV101) in treating Angelman Syndrome. Learn about the upcoming clinical trials by Ovid Therapeutics and their commitment to global accessibility.
• The use of gene therapy for the production of UBE3A in the treatment of Angelman Syndrome. Discussion of future clinical trials
  Explore Agilis Biotherapeutics’ advancements in gene therapy for Angelman Syndrome treatment. Learn about their research, future clinical trials, and commitment to the Angelman Syndrome community.
• Which Way to Autonomous Communication? Aided Language Stimulation Towards Autonomous Communication
  Explore the importance of Augmentative and Alternative Communication (AAC) systems as language, not just pictures. Learn about aided language input, AAC modeling strategies, and the unique developmental trajectory of children with Angelman Syndrome.